Meeting Banner
Abstract #2517

eNOS-/- mice fed with HFD develop progressive non-alcoholic fatty liver disease (NAFLD) which is partially reversible with antihypertensive and hypoglycemic therapy

BegoƱa Lavin Plaza1, Marcelo E Andia2, Thomas Eykyn1, Alkystis Phinikaridou1, Aline Xavier2, and Rene M Botnar1

1Imaging Sciences and Biomedical Engineering, King's College London, London, United Kingdom, 2Radiology department, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile

Liver steatosis or non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries. However, the cause and treatments are still controversial. Nitric oxide (NO) and its derivatives play important roles in the physiology and pathophysiology of the vascular system and liver metabolism. We quantified intraperitoneal fat and liver fat-fraction using 3T MRI in eNOS-/- mice fed with HFD and investigated (1) whether pharmacological treatments for type 2 diabetes and hypertension reduced fat deposition and (2) if the phenotype could be recapitulated by administration of an inhibitor of endothelial NO synthesis (L-NAME) in wild type mice.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.

Keywords